Showing results (521-530 of 595) with videos related to

Sort By:
Pageof 60
Advanced Drug Delivery Reviews|February 4, 2024
Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findingsMichael Z Liao, Dan Lu, Tong Lu, et al.
Turkish Thoracic Journal|February 3, 2022
Determination of Novel Coronavirus Disease (COVID-19) Vaccine Hesitancy Using a Systematic Review Approach Based on the Scientific Articles in PubMed DatabaseAlperen Ergün, Ayşegül Bekar, Bedran Aras, et al.
Toxicology and Applied Pharmacology|March 30, 2018
Effects of continuous bisphenol A exposure from early gestation on 90 day old rat testes function and sperm molecular profiles: A CLARITY-BPA consortium studyEdward Dere, Linnea M Anderson, Susan M Huse, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 22, 2013
The current status of biomarkers for predicting toxicitySarah Campion, Jiri Aubrecht, Kim Boekelheide, et al.
The Journal of Biological Chemistry|June 14, 2013
Inactivation of ceramide synthase 6 in mice results in an altered sphingolipid metabolism and behavioral abnormalitiesPhilipp Ebel, Katharina Vom Dorp, Elisabeth Petrasch-Parwez, et al.
Behavioural Brain Research|February 13, 2017
Hypersocial behavior and biological redundancy in mice with reduced expression of PSD95 or PSD93Daniela Winkler, Fernanda Daher, Liane Wüstefeld, et al.
Pharmaceutical Research|December 1, 2020
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin LymphomaDan Lu, Tong Lu, Rong Shi, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 16, 2024
Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX studyRong Deng, Leonid Gibiansky, Tong Lu, et al.
Biorxiv : the Preprint Server for Biology|May 25, 2026
H2AX C-Terminal Dipeptide Truncation: A Master Switch of the DNA Damage ResponseFaith M Joseph, Matthew V Holt, John M Jerome, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 22, 2019
Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin LymphomaDan Lu, Tong Lu, Leonid Gibiansky, et al.
Pageof 60